- Home
- GNS vs HIND Comparison
GNS vs HIND Comparison
Compare GNS & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNS | HIND |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 12.9M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GNS | HIND |
|---|---|---|
| Price | $0.45 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 917.9K | 21.3K |
| Earning Date | 03-09-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $1.75 |
| 52 Week High | $1.92 | $12.87 |
Technical Indicators
Market Signals| Indicator | GNS | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 48.47 |
| Support Level | $0.36 | $2.02 |
| Resistance Level | $0.48 | $2.93 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 88.53 | 68.29 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.